Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.

Background: Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective strategy for...

Descripción completa

Detalles Bibliográficos
Publicado en:Breast Cancer Research Vol. 21; no. 1
Autores principales: Lee, Jung Ok, Kang, Min Ju, Byun, Won Seok, Kim, Shin Ae, Seo, Il Hyeok, Han, Jeong Ah., Moon, Ji Wook, Kim, Ji Hae, Kim, Su Jin, Lee, Eun Jung, In Park, Serk, Park, Sun Hwa, Kim, Hyeon Soo
Formato: Journal Article
Publicado: BioMed Central 10/22/2019
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=139273776&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 139273776
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        14655411
        8UYJ
      jtl: Breast Cancer Research
      issn: 14655411
      maglogo: N
    pubinfo:
      dt: 10/22/2019
      vid: 21
      iid: 1
      pid: 24147
      pub: BioMed Central
    artinfo:
      ui:
        139273776
        139273776
        NLM31640742
        10.1186/s13058-019-1204-2
        NLM31640742
        139273776
      ppct: 1
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51.
      aug:
        au:
          Lee, Jung Ok
          Kang, Min Ju
          Byun, Won Seok
          Kim, Shin Ae
          Seo, Il Hyeok
          Han, Jeong Ah.
          Moon, Ji Wook
          Kim, Ji Hae
          Kim, Su Jin
          Lee, Eun Jung
          In Park, Serk
          Park, Sun Hwa
          Kim, Hyeon Soo
        affil: Department of Anatomy, Korea University College of Medicine, 126-1, Anam-dong 5-ga, Seongbuk-gu, Seoul, Republic of Korea
      sug:
        subj:
          Breast Neoplasms Metabolism
          Cisplatin Pharmacodynamics
          Drug Resistance, Neoplasm
          Metformin Pharmacodynamics
          Cell Physiology Drug Effects
          Cisplatin Administration and Dosage
          Animals
          Metformin Administration and Dosage
          Breast Neoplasms
          Female
          Antineoplastic Agents, Combined Pharmacodynamics
          Breast Neoplasms Drug Therapy
          Mice
          Drug Synergism
          Antineoplastic Agents Pharmacodynamics
          Genes Drug Effects
          Breast Neoplasms Pathology
          Antineoplastic Agents Administration and Dosage
          Cell Line, Tumor
          Cell Movement Drug Effects
          Female
      ab: Background: Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective strategy for TNBC treatment. Whether metformin enhances the anticancer effects of cisplatin and prevents cisplatin resistance in TNBC cells has not been reported.Methods: Cell viability, wounding healing, and invasion assays were performed on Hs 578T and MDA-MB-231 human TNBC cell lines to demonstrate the anticancer effects of combined cisplatin and metformin treatment compared to treatment with cisplatin alone. Western blotting and immunofluorescence were used to determine the expression of RAD51 and gamma-H2AX. In an in vivo 4T1 murine breast cancer model, a synergistic anticancer effect of metformin and cisplatin was observed.Results: Cisplatin combined with metformin decreased cell viability and metastatic effect more than cisplatin alone. Metformin suppressed cisplatin-mediated RAD51 upregulation by decreasing RAD51 protein stability and increasing its ubiquitination. In contrast, cisplatin increased RAD51 expression in an ERK-dependent manner. In addition, metformin also increased cisplatin-induced phosphorylation of γ-H2AX. Overexpression of RAD51 blocked the metformin-induced inhibition of cell migration and invasion, while RAD51 knockdown enhanced cisplatin activity. Moreover, the combination of metformin and cisplatin exhibited a synergistic anticancer effect in an orthotopic murine model of 4T1 breast cancer in vivo.Conclusions: Metformin enhances anticancer effect of cisplatin by downregulating RAD51 expression, which represents a novel therapeutic target in TNBC management.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N